Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Black Diamond Therapeutics is a clinical-stage precision oncology company developing allosteric inhibitors targeting oncogenic mutations in receptor tyrosine kinases, particularly EGFR and HER2. The company's lead candidate BDTX-1535 targets EGFR mutations in non-small cell lung cancer (NSCLC), with clinical trials ongoing as of early 2026. With zero revenue, negative operating cash flow of $100M annually, and a market cap of $100M, BDTX is a high-risk biotech dependent on clinical trial outcomes and capital markets access.
BDTX is developing mutation-agnostic allosteric inhibitors designed to overcome resistance mechanisms in targeted cancer therapies. The company's MasterKey platform identifies cryptic binding sites on kinases, potentially enabling treatment of broader patient populations than existing ATP-competitive inhibitors. Revenue generation depends on successful Phase 2/3 trials, FDA approval, and commercialization partnerships or direct sales. Pricing power would derive from addressing unmet needs in EGFR-mutant NSCLC patients who progress on current therapies, with potential pricing of $150K-200K annually per patient based on comparable oncology drugs.
BDTX-1535 clinical trial data readouts - objective response rates (ORR), progression-free survival (PFS), and safety profiles in EGFR-mutant NSCLC patients
FDA regulatory milestones including IND clearances, breakthrough therapy designations, or approval decisions
Cash runway announcements and equity financing events - with $100M market cap and negative $100M cash flow, dilution risk is material
Partnership or licensing deals with larger pharma companies for development/commercialization rights
Competitive data from rival EGFR inhibitor programs (Amgen, Janssen, Takeda) targeting similar patient populations
Clinical trial failure risk - BDTX-1535 must demonstrate superior efficacy versus existing EGFR inhibitors (osimertinib, amivantamab) in resistant populations; Phase 2/3 failure would likely render company non-viable
Regulatory approval uncertainty - FDA oncology approvals require robust survival benefit data; accelerated approval pathways depend on ORR in heavily pre-treated populations
Competitive intensity in EGFR-mutant NSCLC space with multiple next-generation inhibitors in development targeting overlapping patient populations
Amgen's patritumab deruxtecan and Janssen's amivantamab have established efficacy in EGFR-mutant NSCLC, creating high bar for differentiation
Larger pharma competitors (AstraZeneca, Takeda) have superior commercialization infrastructure and can outspend in clinical development
Mutation-agnostic approaches may face challenges demonstrating consistent efficacy across heterogeneous patient populations
Capital depletion risk - $100M annual cash burn against $100M market cap suggests imminent need for dilutive financing within 12-18 months
Going concern risk if clinical data disappoints and capital markets close to biotech sector, as occurred in 2022-2023
Potential inability to complete pivotal trials without partnership or substantial equity raise, likely at significant discount to current valuation given recent 42% three-month decline
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact venture capital availability and public market appetite for biotech IPOs/secondaries, affecting capital raising ability. Oncology drug demand is non-discretionary and recession-resistant.
Rising interest rates negatively impact BDTX through two mechanisms: (1) Higher discount rates compress valuations of distant future cash flows, particularly punishing pre-revenue biotechs with 5-7 year commercialization timelines; (2) Reduced risk appetite in capital markets makes equity financing more dilutive or unavailable. With 8.94x current ratio but negative cash flow, BDTX requires periodic capital raises where rate environment materially affects terms.
Minimal direct credit exposure - BDTX operates with minimal debt (0.13 debt/equity ratio). However, credit market conditions indirectly affect biotech sector through venture debt availability and institutional investor risk appetite. Tighter credit conditions correlate with reduced biotech IPO/follow-on activity, constraining financing options.
growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and specialized healthcare funds willing to underwrite binary clinical trial outcomes. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. Recent 42% three-month decline and negative 48% FCF yield indicate momentum investors have exited.
high - Clinical-stage biotechs exhibit extreme volatility around data catalysts, with 30-50% single-day moves common on trial readouts. Small market cap ($100M) amplifies volatility through limited float and institutional ownership. Implied volatility typically 80-120% for biotech options versus 20-30% for large-cap indices.
